Nevro Corp. (NVRO)

11,32 -0,30 (-2,58%) Alla chiusura: 04:00PM EDT

Nevro Corp.

1800 Bridge Parkway
Redwood City, CA 94065
United States
650 251 0005
https://nevro.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 1.215

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Kevin R. Thornal	President, CEO & Director	1,37M	N/D	1974
Mr. Roderick H. MacLeod	Senior VP & CFO	653,1k	N/D	1967
Mr. Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	629,62k	N/D	1974
Mr. Greg Siller	Senior VP & Chief Commercial Officer	419,9k	N/D	1981
Mr. Richard B. Carter	Chief Accounting Officer	N/D	N/D	1971
Mr. Christofer Christoforou	Senior Vice President of Technical Operations	367,4k	N/D	1970
Geeta Kaveti	VP and Chief Compliance & Privacy Officer	N/D	N/D	N/D
Meredith Vornholt	Vice President of Global Marketing	N/D	N/D	N/D
Ms. Shana D. Ross M.B.A.	Senior VP & Chief Human Resources Officer	N/D	N/D	1973
Dr. David Caraway M.D., Ph.D.	Senior VP & Chief Medical Officer	N/D	N/D	1957

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Nevro Corp. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.